Efficacy and Safety of a New 10% Intravenous Immunoglobulin Product in Patients with Primary Immune Thrombocytopenia (ITP)

BACKGROUND: In the current study, we aimed to investigate the efficacy and safety of intravenous immunoglobulin (IVIg)-SN 10%, a new 10% IVIg formulation, in adult patients with severe primary immune thrombocytopenia (ITP; platelet count < 20 × 10(9)/L). METHODS: Patients diagnosed as primary ITP...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Junshik, Bang, Soo-Mee, Mun, Yeung-Chul, Yhim, Ho-Young, Lee, Jaehoon, Lim, Hyeong-Seok, Oh, Doyeun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5934518/
https://www.ncbi.nlm.nih.gov/pubmed/29736158
http://dx.doi.org/10.3346/jkms.2018.33.e142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5934518/
https://www.ncbi.nlm.nih.gov/pubmed/29736158
http://dx.doi.org/10.3346/jkms.2018.33.e142

Ejemplares similares